Djukanovic L, Susic D, Jovanovic D, Varagic J, Jovanovic D, Starcevic A, Kartaljevic G, Bogdanovic G
Institute of Urology and Nephrology, University Clinical Center, Belgrade, Yugoslavia.
Isr J Med Sci. 1994 Oct;30(10):742-6.
The effects of captopril and hydralazine on morphologic changes and clinical course of adriamycin nephropathy in spontaneously hypertensive rats (SHR) were examined. The rats were followed for 18 weeks after adriamycin injections. At week 1 they were randomly assigned to receive no antihypertensive treatment, captopril 60 mg/kg per day or hydralazine 6 mg/kg per day. A control group of SHR not treated with adriamycin was also included in the study. Both antihypertensive agents normalized systemic blood pressure, but failed to prevent proteinuria, mesangial expansion and renal failure progression. At the end of the study all adriamycin-treated groups had the same degree of renal failure irrespective of whether blood pressure was well controlled with captopril or hydralazine or whether hypertension persisted. Nevertheless, antihypertensive therapy slowed down renal function deterioration in the early stage of adriamycin nephropathy. Treatment with captopril also reduced the development of glomerular sclerosis.
研究了卡托普利和肼屈嗪对自发性高血压大鼠（SHR）阿霉素肾病形态学变化和临床病程的影响。阿霉素注射后对大鼠进行了18周的随访。在第1周，它们被随机分配接受不进行抗高血压治疗、每天60mg/kg卡托普利或每天6mg/kg肼屈嗪。研究中还包括一组未用阿霉素治疗的SHR作为对照组。两种抗高血压药物均使全身血压正常化，但未能预防蛋白尿、系膜扩张和肾衰竭进展。研究结束时，所有接受阿霉素治疗的组无论血压是否用卡托普利或肼屈嗪良好控制或高血压是否持续，均有相同程度的肾衰竭。然而，抗高血压治疗在阿霉素肾病早期减缓了肾功能恶化。卡托普利治疗还减少了肾小球硬化的发生。
